Kato Rans

Elective para-aortic RT + 24 months ADT shows promising results in pN1 prostate cancer! In the PART trial (n=96), 5y clinical RFS reached 91% in the adjuvant setting vs 63% salvage (p=0.029) with acceptable toxicity. Early intervention matters. #ESTRO2025 #RadOnc #ProstateCancer

This Tuesday, I had the honor of successfully defending my PhD at the @KU_Leuven titled: "𝐓𝐡𝐞 𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐑𝐨𝐥𝐞 𝐨𝐟 𝐑𝐚𝐝𝐢𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐢𝐧 𝐇𝐢𝐠𝐡-𝐑𝐢𝐬𝐤 𝐚𝐧𝐝 𝐎𝐥𝐢𝐠𝐨𝐦𝐞𝐭𝐚𝐬𝐭𝐚𝐭𝐢𝐜 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐂𝐚𝐧𝐜𝐞𝐫." I am immensely grateful to my promoter Prof. Dr. @GertMeerleer and co-promoter Prof. Dr. @joniau for their guidance and support throughout this journey. A heartfelt thank you to my jury members Dr. @alison_tree, Dr. @AmeyeFilip, Prof. Dr. @MaartenAlbersen, and Prof. Dr. Herlinde Dumez for their insightful feedback and constructive discussions. A special thanks to Prof. Dr. @heinvanpoppel and Prof. Dr. An Coosemans for your presence and support. I also want to express my gratitude to the @Stkstichting and Rising Tide Foundation for Clinical Cancer Research for their financial support, which made this research possible. Lastly, thank you to everyone who contributed to these projects, and to all the patients who placed their trust in our team!

Phase 3 MEDCARE in M+CRPC is up and running! And it is running well! If interested: let us know. @KatoRans @joniau @karolien_goffin @BarbaraJereczek @CVulsteke #SBRT #SABR #ProstateCancer #hope

Thank you Rising Tide for the important funding we received for our phase 3 MEDCARE RCT in mCRPC patients ⁦@KatoRans⁩ ⁦@joniau⁩ ⁦@karolien_goffin⁩ #estro #STK #wijook

🌟 Experience the latest of urology at #ScientificSummits 2024! Join us in 📍Leuven on May 24-25 for groundbreaking discussions on urothelial, prostate, and kidney cancer. Register now! 👇🔗scientificsummits.eu/conferences/sc…

▶️ Prospective, single-arm, phase II trial ✅ Progression-directed therapy resulted in a median NEST-free survival of 17 months ❌ No early or late grade ≥3 toxicity ⚠️ Significantly longer NEST-FS for patients treated on all blinded PSMA PET-CT positive lesions

Proud to present the final results of the MEDCARE phase II study published in @EurUrolOncol! Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer! ⚡️ @GertMeerleer @joniau @karolien_goffin @CharlienBerghen @Haustermans authors.elsevier.com/c/1i~Pq9Cfv--d…

Honoured to present the Radiation Oncologist’s Perspective regarding the treatment of Prostate Cancer at #EAU24 #ProstateCancer @GertMeerleer @joniau

Oligometastatic Recurrent Prostate Cancer: Whether To Intensify Treatm... sciencedirect.com/science/articl…

🚀 BeGUS Post-ASCO GU Virtual Symposium 2024! Dive into the latest on prostate, urothelial, & renal cancers! 📅 March 25-26 | 🖥️ Zoom | 🌟 Interactive Sessions & Panels 👉 Reserve your spot now: medcc.be/registration-b… #BeGUS2024 #Urology #CancerResearch #VirtualCongress

Happy and grateful to present our results of phase 2 MEDCARE trial in oligoprogressive metastatic castration-refractory prostate cancer @ASTRO23 SBRT postpones need for new systemic treatment with 1.5 years! More to follow. @KatoRans @joniau @karolien_goffin @Mat_Guc

Ready for Scientific Summits. Top content in top location. #scisu @joniau @KarelDecaestec1 @KatoRans @ClaessensMarc @GevaertThomas @adamsthomas @CVulsteke

@BioMedCentral @GertMeerleer @CharlienBerghen @joniau @AmeyeFilip @OlivierDeHertogh @JuliedenHartog @CedericDraulans @HerlindeDumez @benediktengels2 @KarolienGoffin @NickLiefhooghe @kennethpoels @CarlSalembier @KoenSlabbaert @HansVandendriessche @ben_vanneste

Proud to present the protocol of the SPARKLE Trial published in @BioMedCentral Oligorecurrent prostate cancer: adding systemic treatment to metastasis-directed therapy: key to long-lasting event-free survival? 👇 @GertMeerleer @CharlienBerghen @joniau #article-info" target="_blank" rel="nofollow noopener">bmccancer.biomedcentral.com/articles/10.11…

Current Issue: Another Step Towards the Acceptance of Metastasis-directed Therapy in Low-volume Metastatic Prostate Cancer buff.ly/3Poku2c @GertMeerleer @KatoRans @joniau @CharlienBerghen #prostatecancer #urology #oncology #MedTwitter

🧵Dr. Charlien Berghen's research team reviewed the role of #radiation therapy and #particle therapy in renal cell carcinoma (#RCC)❤️ ✅Photon #SBRT (Stereotactic body radiotherapy) 📝#PBT ⤵️#CIRT (carbon ions)

AddThis | Home A plea for metastasis-directed therapy in low-volume castration-refractory prostate cancer. @joniau @KatoRans @CharlienBerghen @AlbertoBossial #prostatecancer #SBRT #MEDCARE authors.elsevier.com/a/1f9DS9Cfv-t-…

Looking Forward to the Scientific Summits!

Join the discussion on postoperative radiation therapy in prostate cancer #case @GertMeerleer @joniau @KatoRans what would you advise to your patient? AddThis | Home authors.elsevier.com/a/1f3K~1Hx528S…

📢SPARKLE trial is officially open 📢 Metastasis-Directed Therapy for Oligorecurrent PCa Open-label ph 3 trial (n=873) 👉Arm A: MDT 👉Arm B: MDT + 1m ADT 👉Arm C: MDT + 6m ADT + Enza #prostatecancer #radonc @GertMeerleer @CharlienBerghen @joniau clinicaltrials.gov/ct2/show/NCT05…